Practical Application Corner – Journal Club.

The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) is unclear.

Reveals that clonal hematopoiesis mutations within tumor microenvironments worsen outcomes — uniting hematology and solid tumor biology.

DLL3-targeted bispecific T-cell engager delivers the first real survival breakthrough in SCLC in decades — new benchmark for immuno-engagers.

Transforms a historically lethal subset into a treatable disease with targeted triplet therapy; establishes new first-line standard.

Immunotherapy replaces surgery for localized dMMR cancers — a paradigm shift proving organ preservation with 100% complete response rate.